Location

Virtual

Event Website

https://www.medschool.lsuhsc.edu/genetics/2024_medical_student_research_poster_symposium.aspx

Presentation Date

5-11-2024 12:00 PM

Description

Introduction:

Lung Cancer (LC) remains the leading cause of cancer-related deaths, with Colorectal Cancer (CRC) being the third leading cause of cancer-related deaths in the US. Patients diagnosed with metastatic CRC may have tumors arising in locations such as the liver, lungs, and peritoneum. Although CRC and lung cancer are among the most common cancers worldwide, synchronous presentation of these cancers is not very common and not well studied. Our study aims to describe the incidence, treatment, and clinical outcomes of patients with synchronous lung, and colorectal cancer.

Methods:

We conducted an 11-year analysis of the Nationwide Inpatient Sample (NIS) database (20022012). All adult (age≥18y) patients admitted with a diagnosis of CRC were included. Data abstracted include demographics, malignancy-related variables, treatment, and operative interventions. We excluded patients who had lung metastasis from CRC. Our primary outcome measures were the incidence of synchronous CRC and lung cancer, operative treatment patterns, and mortality.

Results:

Out of 1,198,421 patients admitted with a CRC diagnosis, 6,231 (0.52%) had synchronous lung cancer. Overall, mean age was 61±15y, 75% were male, and 63% were white. The majority of patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (76%). The majority of CRC patients (79%) had recto-sigmoid tumors. Only 11.2% underwent surgical management. No significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p=0.21). The overall mortality rate was 54%.

Conclusion:

The incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. Treatment options for these patients should be tailored to the individual patient. Genetic, biomarker and epidemiological studies are required to elucidate the potential connection between lung and colon cancer.

Comments

Mentor: Valentine Nfonsam, MD, MS, FACS, FACRS LSUHSC, Chair, Department of Surgery

Presentation: https://www.youtube.com/watch?v=B3TcZg6j2Ww

Additional Files
CruzAlejandroAbstract.pdf (107 kB)
Download

Share

COinS
 
Nov 5th, 12:00 PM

Incidence, Treatment and Outcomes of Patients with Synchronous Lung and Colorectal Malignancies: A Nationwide Inpatient Sample Database (NIS) Analysis

Virtual

Introduction:

Lung Cancer (LC) remains the leading cause of cancer-related deaths, with Colorectal Cancer (CRC) being the third leading cause of cancer-related deaths in the US. Patients diagnosed with metastatic CRC may have tumors arising in locations such as the liver, lungs, and peritoneum. Although CRC and lung cancer are among the most common cancers worldwide, synchronous presentation of these cancers is not very common and not well studied. Our study aims to describe the incidence, treatment, and clinical outcomes of patients with synchronous lung, and colorectal cancer.

Methods:

We conducted an 11-year analysis of the Nationwide Inpatient Sample (NIS) database (20022012). All adult (age≥18y) patients admitted with a diagnosis of CRC were included. Data abstracted include demographics, malignancy-related variables, treatment, and operative interventions. We excluded patients who had lung metastasis from CRC. Our primary outcome measures were the incidence of synchronous CRC and lung cancer, operative treatment patterns, and mortality.

Results:

Out of 1,198,421 patients admitted with a CRC diagnosis, 6,231 (0.52%) had synchronous lung cancer. Overall, mean age was 61±15y, 75% were male, and 63% were white. The majority of patients with synchronous malignancies (56%) had advanced CRC with non-small cell lung cancer (76%). The majority of CRC patients (79%) had recto-sigmoid tumors. Only 11.2% underwent surgical management. No significant difference was noted in the proportion of patients first treated for their CRC relative to those treated for their lung cancer first (p=0.21). The overall mortality rate was 54%.

Conclusion:

The incidence of synchronous occurrence of CRC and lung cancer is low, but the mortality is very high. Diagnosis of synchronous cancer is typically incidental. Treatment options for these patients should be tailored to the individual patient. Genetic, biomarker and epidemiological studies are required to elucidate the potential connection between lung and colon cancer.

https://digitalscholar.lsuhsc.edu/sommrd/2024MSRD/Posters/29